December 24, 2025 16:00 ET | Source: XTL Biopharmaceuticals Ltd. RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL…
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF)…
Hong Kong, Nov. 21, 2025 (GLOBE NEWSWIRE) -- DarkIris Inc. (Nasdaq: DKI) (the “Company” or “DarkIris”), a comprehensive technology enterprise…
STOCKHOLM, Sept. 22, 2025 /PRNewswire/ -- A health solution designed to improve iron absorption in women has garnered international acclaim,…